GLAUCOMA 360

Robert L. Stamper, MD, discusses the findings of a study analyzing the effects of corneal mechanics on IOP, presented during the virtual Glaucoma 360 meeting.

During the 2021 Glaucoma 360 meeting, Ruth D. Williams, MD, speaks on the highlights and key findings from the EAGLE study, which showed clear lens extraction surgery may be a better initial treatment for some glaucoma patients.

Andrew Iwach, MD, and Adrienne Graves, PhD, co-founders of Glaucoma 360, preview what attendees will experience at the 2021 version of the CME/CE Symposia, Annual Gala, and New Horizons Forum.

Amid a pandemic, the Glaucoma Research Foundation is holding its annual gala online, funding aspirations for a glaucoma-free world with a goal of raising $1 million.

Pharmaceutical representatives share what keeps them up at night within the ophthalmic space.

In this fourth installment on "2020 vision," pharmaceutical representatives share their outlook on what lies ahead for glaucoma innovations within the ophthalmic space.

How gonioscopy can offer ophthalmologists an option in treating patients with glaucoma

Researchers must weigh emotional, financial, and reputational considerations

Trabeculectomy may offer better results with more severe glaucoma

Technology is off to a good start, but improvements still needed

Diagnostic and monitoring advances in glaucoma need fine-tuning

With an eye on innovation, money is driving research of new therapies and devices.

Industry develops creative approaches to help increase patient medication adherence

Panel discusses IOP monitoring, drug delivery, data collection

ICYMI: Nir Israeli, co-founder and CEO of Sanoculis discusses the company's new alternative surgical procedure for glaucoma designed to create a single-patient-use sterile tool and a multi-use external machine.

For many physicians, “moral injury” may be actual issue

ICYMI: Chris Adams, CEO of Diopter Corp, discusses the company's drug delivery contact lens technology in the pipeline that works to treat ocular surface disease, during the 2020 Glaucoma 360 meeting in San Francisco, California.

ICYMI: Ramin Valian, vice president of International Glaucoma, Reimbursement and Pipeline at Allergan, discusses glaucoma from a therapeutics/diagnostics and big data sets standpoint during the 2020 Glaucoma 360 meeting.

High-level observations for how the latest developments can help glaucoma specialists solve problems to achieve the utmost in patient care

Besides traditional medications, here are some of the many novel approaches to treat patients with glaucoma

There are other mimickers of NTG that should be kept in mind

New products increase the chance of early diagnosis

ICYMI: Daria Lemann Blumenthal, CEO of BELKIN Laser, Ltd., discusses the company's current initiative of developing an automated one-second laser therapy for glaucoma called direct selective laser trabeculoplasty (DSLT).

New therapies on the horizon offer options for slowing progression

ICYMI: Yvonne Ou, MD, discusses her presentation on "Apps for the visually challenged," during the 2020 Glaucoma 360 annual meeting in San Francisco, California.

Novel technologies range from invasive to non-invasive approaches

Dale Heuer, MD discusses the importance of ophthalmologists identifying and providing more aggressive treatment care for patients with low/high risks of developing glaucoma.

ICYMI: Thomas Samuelson, MD,shares the key highlights from his presentation "Stents, trabs, and tubes: Decision-making in surgical glaucoma."